
|Videos|December 9, 2021
Recent Data Surrounding the Appropriate Candidates for Long-Acting Cabotegravir for HIV Prevention
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Advertisement
Pharmacy Times spoke with Dr. Elizabeth Sherman, PharmD, about her session at the ASHP Midyear 2021 conference, titled "Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection”.
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Can Close the Opioid Addiction Care Gap
2
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
3
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
4
The Return of Belantamab Mafodotin: Past Lessons, Present Promise, and Future Impact
5
















































































































































































































